Gerinnungszentrum Rhein-Ruhr Aerztepartnerschaft Dr. med. Hannelore Rott Fachaerztin fuer Transfusionsmedizin Haemostaseologie Dr. med. Susan Halimeh Fachaerztin fuer Transfusionsmedizin Haemostaseologie Dr. med. Guenther Kappert Facharzt fuer Laboratoriumsmedizin Haemostaseologie
- Address
- Koenigstrasse 13, Altstadt, 47051 Duisburg, Germany
Gerinnungszentrum Rhein-Ruhr - Specialized Center for Hemostaseology and Transfusion Medicine
The Gerinnungszentrum Rhein-Ruhr represents a leading German center of excellence in hemostaseology and transfusion medicine, specializing in the diagnosis and treatment of inherited and acquired bleeding and clotting disorders. Led by specialized physicians in transfusion medicine, hemostaseology, and laboratory medicine, the center conducts cutting-edge clinical research focused on rare coagulation disorders and innovative therapeutic approaches.
- Hemophilia A with inhibitor management and immune tolerance induction (ITI) protocols
- Von Willebrand Disease, including Type 3 VWD treatment strategies
- Congenital antithrombin deficiency perioperative management
- Novel prophylactic therapies for inherited bleeding disorders
The center's research portfolio demonstrates particular expertise in managing complex coagulation factor deficiencies and evaluating advanced treatment modalities including factor replacement therapies and next-generation biologics. Their participation in international investigator-initiated trials positions them at the forefront of developing improved outcomes for patients with rare bleeding disorders, with special focus on inhibitor eradication strategies and prophylactic treatment regimens for patients undergoing surgical procedures or experiencing spontaneous bleeding episodes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gerinnungszentrum Rhein-Ruhr Aerztepartnerschaft Dr. med. Hannelore Rott Fachaerztin fuer Transfusionsmedizin Haemostaseologie Dr. med. Susan Halimeh Fachaerztin fuer Transfusionsmedizin Haemostaseologie Dr. med. Guenther Kappert Facharzt fuer Laboratoriumsmedizin Haemostaseologie
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of Antithrombin III Human in Patients with Congenital Antithrombin Deficiency Undergoing Surgical Procedures or Parturition | Octapharma AG | Phase III | Recruiting | Feb 2023 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emicizumab | 2 | Unknown | 2020-01-14 | 2025-06-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.